Generated by AI
Legend Biotech Corporation ADR is a biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing cell therapies for oncology and other serious diseases. The company’s work centers on advanced immunotherapy platforms, including chimeric antigen receptor T-cell approaches and other cellular therapies designed to target hard-to-treat cancers. Its portfolio is led by CARVYKTI, a BCMA-directed CAR-T therapy used in multiple myeloma, and it also supports additional investigational cell therapy programs across hematologic and solid tumor settings. Legend Biotech serves patients and healthcare providers through a global footprint spanning the United States, China, and Europe, combining research, manufacturing, and commercialization capabilities within a single operational model. As an ADR, Legend Biotech Corporation ADR provides market access to a company positioned at the intersection of biotechnology innovation and specialty cancer treatment.
Website2101 Cottontail Lane
Somerset, NJ, 08873
United States
The latest articles about LEGN.
Summary of Nov 16's posts. Generated by AI.
Summary of Nov 11's posts. Generated by AI.
Summary of Jun 2's posts. Generated by AI.
Summary of Aug 18's posts. Generated by AI.
Investors talking about LEGN also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.